Archives of Pharmacal Research

The Pharmaceutical Society of Korea (대한약학회)
권호 표지

Identification of New Urinary Metabolites of Byakangelicin, a Component of Angelicae dahuricae Radix, in Rats

  • Kwon, Oh-Seung (Toxicology Lab., Bioanalysis and Biotransformation Research Center, Korea Institute of Science and Technology) ;
  • Song, Yun-Seon (Toxicology Lab., Bioanalysis and Biotransformation Research Center, Korea Institute of Science and Technology) ;
  • Shin, Kuk-Hyun (Natural Products Research Institute, Seoul National University) ;
  • Ryu, Jae-Chun (Toxicology Lab., Bioanalysis and Biotransformation Research Center, Korea Institute of Science and Technology)
  • Published : 2003.08.01
Download PDF
⟨ Previous Next ⟩

Abstract

Byakangelicin, 9-(2,3-dihydroxy-2-methylbutoxy)-4-methoxy-7H- furo[3,2-g][l]benzopyran-7-one (BKG), a component of Angelicae dahuricae Radix, is considered to be an inhibitor of aldose reductase for the treatment of diabetic cataract. An analytical method for the isolation of BKG developed by high-performance liquid chromatography has been reported. No literature on the metabolism of BKG, however, has been found. With the purpose of identifying new metabolites of BKG, BKG (100 mg/kg) was orally administered to Sprague-Dawley rats via a gavage. Using a metabolic cage, urine was collected for 24 h, and the urine samples were extracted by liquid-liquid extraction. For structural identification of new urinary metabolites of BKG, various instrumental analyses were conducted by gas-chromatography/mass spectrometry, high-performance liquid chromatography/diode array detector, liquid chromatography/mass spectroscopy with thermospray interface and $^1H$ nuclear magnetic resonance spectroscopy. Two metabolites produced from the Ο-demethylation or Ο-dealkylation of BKG were newly identified, and another new but unknown metabolite was assumed to be the hydroxylated form of BKG. These results indicate that the major metabolic products of BKG are formed by Ο-demethylation or Ο-dealkylation of BKG side chains.

Keywords

References

  1. Ao, S., Kikuchi, C., Ono, T., and Notsu, Y., Effect of instillation of aldose reductase inhibitor FR74366 on diabetic cataract. Invest. Ophthalmol. Vis. Sci., 32 (12), 3078-3083 (1991)
  2. Beyer-Mears, A., Mistry, K., Diecke, F. P., and Cruze, E., Zopolrestat prevention of proteinuria, albuminuria and cataractogenesis in diabetes mellitus. Pharmacology, 52 (5), 292-302 (1996) https://doi.org/10.1159/000139394
  3. Beyer-Mears, A. and Cruz, E., Reversal of diabetic cataract by sorbinil, an aldose reductase inhibitor. Diabetes, 34 (1), 15-21 (1985) https://doi.org/10.2337/diabetes.34.1.15
  4. Kador, P. F., The role of aldose reductase in the development of diabetic complications. Med. Res. Rev., 8, 325-352 (1988) https://doi.org/10.1002/med.2610080302
  5. Kim, Y. B., Oh, Y. H., Park, I. Y., and Shin, K. H., Crystal structure of byakangelicin. Arch. Pharm. Res., 25 (3), 275-279 (2002) https://doi.org/10.1007/BF02976625
  6. Kimura, Y., Ohminami, H., Arichi, H., Okuda, H., Baba, K., Kozawa, M., and Arichi, S., Effects of various coumarins from roots of Angelica dahurica on actions of adrenalin, ACTH and insulin in fat cells. Planta Med., 45, 183-187 (1982) https://doi.org/10.1055/s-2007-971370
  7. Oh, H, Lee, H. S., Kim, T., Chai, K. Y., Chung, H. T., Kwon, T. O., Jun, J. Y., Jeong, O. S., Kim, Y. C., and Yun, Y. G., Furonocoumarins from Angelica dahurica with hepatoprotective activity on tacrine-induced cytotoxicity in Hep G2 cells. Planta Med., 68(5), 463-464 (2002) https://doi.org/10.1055/s-2002-32075
  8. Saiki, Y., Morinaga, K., Okegawa, O., Sakai, S., and Amaya, Y., On the coumarins of the roots of Angelica dahurica Benth et Hook. Yakugaku Zasshi., 91(12), 1313-1317 (1971) https://doi.org/10.1248/yakushi1947.91.12_1313
  9. Shin, K. H., Chung, M. S., and Cho, T. S., Effects of furanocoumarins from Angelica dahurica on aldose reductase and galactosemic cataract formation in rats. Arch. Pharm. Res., 17(5), 331-336 (1994) https://doi.org/10.1007/BF02974172
  10. Shin, K. H., Kang, S. S., and Chi, H. J., Determination of byakangelicin in Angelicae Radix by high-performance liquid chromatography. Kor. J. Pharmacog., 3, 239-241 (1990)
  11. Shin, K. H. and Woo, W. S., Inhibition of hepatic microsomal drug-metabolizing enzyme by imperatorin. Arch. Pharm. Res., 9, 81-85 (1986) https://doi.org/10.1007/BF02857215
  12. Terashima, H., Hama, K., Yamamoto, R., Tsuboshima, M., Kikkawa, R., Hatanaka, I., and Shigeta, Y., Effects of a new aldose reductase inhibitor on various tissues in vitro. J. Pharmacol. Exp. Ther., 229, 226-230 (1984)
  13. Tomlinson, D. R., Stevens, E. J., and Diemel, L. T., Aldose reductase inhibitors and their potential for the treatment of diabetic complications. Trends Pharmacol. Sci., 15, 293-297 (1994) https://doi.org/10.1016/0165-6147(94)90010-8